A Case of Metastatic Castration-Resistant Prostate Cancer With Mutation Responding to Niraparib.
1/5 보강
[INTRODUCTION] A certain proportion of prostate cancers have alterations in homologous recombination repair (HRR)- related genes.
APA
Sato Y, Fujii Y, et al. (2025). A Case of Metastatic Castration-Resistant Prostate Cancer With Mutation Responding to Niraparib.. IJU case reports, 8(6), 578-582. https://doi.org/10.1002/iju5.70093
MLA
Sato Y, et al.. "A Case of Metastatic Castration-Resistant Prostate Cancer With Mutation Responding to Niraparib.." IJU case reports, vol. 8, no. 6, 2025, pp. 578-582.
PMID
41185726 ↗
Abstract 한글 요약
[INTRODUCTION] A certain proportion of prostate cancers have alterations in homologous recombination repair (HRR)- related genes. poly ADP-ribose polymerase (PARP) inhibitors have been approved for metastatic castration-resistant prostate cancer (mCRPC) with mutations in the gene. For other HRR-related genes, there is insufficient evidence to determine whether PARP inhibitors are effective or not.
[CASE PRESENTATION] The patient was a 59-year-old man with mCRPC. FoundationOne CDx was performed using surgical specimens and detected a pathogenic variant of the gene, and the expert panel recommended administration of niraparib by patient-proposed healthcare services. Therefore, the patient was enrolled in the BELIEVE Trial and started on niraparib, which showed a marked decrease in PSA and a reduction in metastatic lesions. However, PSA subsequently began to rise and metastatic lesions were enlarged, so treatment was discontinued at 25 weeks.
[CONCLUSION] Niraparib was effective for mCRPC with gene mutation.
[TRIAL REGISTRATION] The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE) (NCCH1901/jRCTs031190104).
[CASE PRESENTATION] The patient was a 59-year-old man with mCRPC. FoundationOne CDx was performed using surgical specimens and detected a pathogenic variant of the gene, and the expert panel recommended administration of niraparib by patient-proposed healthcare services. Therefore, the patient was enrolled in the BELIEVE Trial and started on niraparib, which showed a marked decrease in PSA and a reduction in metastatic lesions. However, PSA subsequently began to rise and metastatic lesions were enlarged, so treatment was discontinued at 25 weeks.
[CONCLUSION] Niraparib was effective for mCRPC with gene mutation.
[TRIAL REGISTRATION] The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE) (NCCH1901/jRCTs031190104).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Oral Environment of Esophageal Cancer Patients, the Incidence of Complications, and Long-Term Prognoses.
- Anticancer activity of Pseudomonas fluorescens lectin (PFL) targeting high-mannose glycans on breast cancer cells.
- Impact of BRAF, TERT, and novel mutations on the efficacy of lenvatinib for advanced papillary thyroid cancer: A national genomic database analysis.
- Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- An innovative treatment for lung cancer using gene-engineered human-induced pluripotent stem cell-derived natural killer cells.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study.
- Return of genome-informed risk-assessment results for common conditions to 23,840 adults and children: An eMERGE network study.
- Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD-1 Inhibitor and Niraparib in GErm-Line-mutAted Metastatic Breast Cancer.
- Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma.
- Psychological Distress and Quality of Life in Families With a Germline CDKN2A Pathogenic Variant.
- Toxicities of PARP inhibitors in genitourinary cancers.